leisure time -WSS

leisure time

author：entertainment 2025-08-12 11:29:47 - browse：26878

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： NIH study of ME/CFS points to clear biological hallmarks

hotspot

WSS

Why sickle cell disease is getting the first CRISPR treatment

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Medicare inequities exacerbate Puerto Rico’s health disparities

Pfizer plans to depart BIO

hotspot

leisure time

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Alabama IVF ruling threatens families facing fatal genetic disease

23andMe had bad news about my health. I wish a person had delivered it

STAT readers on older presidents, polypills, Medicare, and more

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What PEPFAR has meant on the ground in Ukraine

Medical records are filled with copy

He's a Nobel laureate. Critics say he was misleading on Covid

Virginia high school admissions case could be legal follow

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Wikipedia

What PEPFAR has meant on the ground in Ukraine

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Medicare inequities exacerbate Puerto Rico’s health disparities

Patients' immediate access to test results puts radiologists in a bind

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

hotspot

leisure time

hotspot

knowledge